Introduction

Marco Del Quiotto, MD-PhD-FACS is professor in the Department of Surgery at University of Colorado School of Medicine. He's here now to discuss his new publication, Adjunct Chemotherapy in Resected Pancreatic Adno Carsonoma following Neo-AdJunct Chemotherapy Benefits Survival. The standard of care for patients that we call primary is actable today is still considered surgery followed by edge-of-ant chemotherapy. But many centers are going in the direction to give Neo-Adjunct treatment of the majority of patients with pancreatic cancer.